Free Trial

HEALTHCARE: Bayer (BAYNGR: Baa2 neg / BBB / BBB): Trial win

HEALTHCARE
  • Positive: Trial win in Philadelphia Court of Appeals. 14th win in last 20 trials
  • Note: The US Environmental Protection Agency deems RoundUp/Glyphosate to be safe.
  • It is only the IARC (International Agency for Research on Cancer (part of WHO)) that considers glypho to be a risk.
  • Bayer is using the decision at the Third Circuit Court of Appeals that FIFRA legislation covers Bayer to argue its position in other trials.
68 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.
  • Positive: Trial win in Philadelphia Court of Appeals. 14th win in last 20 trials
  • Note: The US Environmental Protection Agency deems RoundUp/Glyphosate to be safe.
  • It is only the IARC (International Agency for Research on Cancer (part of WHO)) that considers glypho to be a risk.
  • Bayer is using the decision at the Third Circuit Court of Appeals that FIFRA legislation covers Bayer to argue its position in other trials.